Search Results - "MUNZERT, Gerd" :: K.UTB vyhledávací portál | TBU Library Retrieval Portal

Anti-B-Cell Maturation Antigen BiTE Molecule AMG 420 Induces Responses in Multiple Myeloma

Anti-B-Cell Maturation Antigen BiTE Molecule AMG 420 Induces Responses in Multiple Myeloma

by Topp, Max S, Duell, Johannes, Zugmaier, Gerhard, Attal, Michel, Moreau, Philippe, Langer, Christian, Krönke, Jan, Facon, Thierry, Salnikov, Alexey V, Lesley, Robin, Beutner, Karl, Kalabus, James, Rasmussen, Erik, Riemann, Kathrin, Minella, Alex C, Munzert, Gerd, Einsele, Hermann
Published in Journal of clinical oncology (10.03.2020)

Get full text

Journal Article

Phase I Dose Escalation and Pharmacokinetic Study of BI 2536, a Novel Polo-Like Kinase 1 Inhibitor, in Patients With Advanced Solid Tumors

Phase I Dose Escalation and Pharmacokinetic Study of BI 2536, a Novel Polo-Like Kinase 1 Inhibitor, in Patients With Advanced Solid Tumors

by MROSS, Klaus, FROST, Annette, STEINBILD, Simone, HEDBOM, Susanne, RENTSCHLER, Jochen, KAISER, Rolf, ROUYRRE, Nicolas, TROMMESHAUSER, Dirk, HOESI, Cornelia E, MUNZERT, Gerd
Published in Journal of clinical oncology (01.12.2008)

Get full text

Journal Article

Phase I trial of volasertib, a Polo-like kinase inhibitor, plus platinum agents in solid tumors: safety, pharmacokinetics and activity

Phase I trial of volasertib, a Polo-like kinase inhibitor, plus platinum agents in solid tumors: safety, pharmacokinetics and activity

by Awada, Ahmad, Dumez, Herlinde, Aftimos, Philippe G., Costermans, Jo, Bartholomeus, Sylvie, Forceville, Kathleen, Berghmans, Thierry, Meeus, Marie-Anne, Cescutti, Jessica, Munzert, Gerd, Pilz, Korinna, Liu, Dan, Schöffski, Patrick
Published in Investigational new drugs (01.06.2015)

Get full text

Journal Article

Bortezomib, Dexamethasone, and Fibroblast Growth Factor Receptor 3–Specific Tyrosine Kinase Inhibitor in t(4;14) Myeloma

Bortezomib, Dexamethasone, and Fibroblast Growth Factor Receptor 3–Specific Tyrosine Kinase Inhibitor in t(4;14) Myeloma

by BISPING, Guido, WENNING, Doris, VOLPERT, Sarah, MESTERS, Rolf M, BERDEL, Wolfgang E, KIENAST, Joachim, KROPFF, Martin, GUSTAVUS, Dirk, MÜLLER-TIDOW, Carsten, STELLJES, Matthias, MUNZERT, Gerd, HILBERG, Frank, ROTH, Gerald J, STEFANIC, Martin
Published in Clinical cancer research (15.01.2009)

Get full text

Journal Article

$An Open-label Dose-escalation Study of BIBF 1120 in Patients with Relapsed or Refractory Multiple Myeloma$

An Open-label Dose-escalation Study of BIBF 1120 in Patients with Relapsed or Refractory Multiple Myeloma

by KROPFF, Martin, KIENAST, Joachim, LISPING, Guido, BERDEL, Wolfgang E, GASCHLER-MARKEFSKI, Birgit, STOPFER, Peter, STEFANIC, Martin, MUNZERT, Gerd
Published in Anticancer research (01.10.2009)

Get full text

Journal Article

CD44v6: a target for antibody-based cancer therapy

CD44v6: a target for antibody-based cancer therapy

by HEIDER, Karl-Heinz, KUTHAN, Hartmut, STEHLE, Gerd, MUNZERT, Gerd
Published in Cancer Immunology, Immunotherapy (01.07.2004)

Get full text

Journal Article

Growth inhibition and induction of apoptosis in acute myeloid leukemia cells by new indolinone derivatives targeting fibroblast growth factor, platelet-derived growth factor, and vascular endothelial growth factor receptors

Growth inhibition and induction of apoptosis in acute myeloid leukemia cells by new indolinone derivatives targeting fibroblast growth factor, platelet-derived growth factor, and vascular endothelial growth factor receptors

by Kulimova, Emma, Oelmann, Elisabeth, Bisping, Guido, Kienast, Joachim, Mesters, Rolf M., Schwäble, Joachim, Hilberg, Frank, Roth, Gerald J., Munzert, Gerd, Stefanic, Martin, Steffen, Björn, Brandts, Christian, Müller-Tidow, Carsten, Kolkmeyer, Astrid, Büchner, Thomas, Serve, Hubert, Berdel, Wolfgang E.
Published in Molecular cancer therapeutics (01.12.2006)

Get full text

Journal Article

$Phase I Dose-Escalation Trial of BI 2536, a Polo-Like Kinase 1 Inhibitor, in Relapsed and Refractory Non-Hodgkin's Lymphoma$

Phase I Dose-Escalation Trial of BI 2536, a Polo-Like Kinase 1 Inhibitor, in Relapsed and Refractory Non-Hodgkin's Lymphoma

by Vose, Julie M., Young, Anas, Friedberg, Jonathan W., Waller, Edmund K., Cheson, Bruce D., Trommeshauser, Dirk, Munzert, Gerd
Published in Blood (16.11.2008)

Get full text

Journal Article

A phase I, dose-escalation study of the novel Polo-like kinase inhibitor volasertib (BI 6727) in patients with advanced solid tumours

A phase I, dose-escalation study of the novel Polo-like kinase inhibitor volasertib (BI 6727) in patients with advanced solid tumours

by Schöffski, Patrick, Awada, Ahmad, Dumez, Herlinde, Gil, Thierry, Bartholomeus, Sylvie, Wolter, Pascal, Taton, Martine, Fritsch, Holger, Glomb, Patricia, Munzert, Gerd
Published in European journal of cancer (1990) (01.01.2012)

Get full text

Journal Article

Molecular cloning of the human histamine H2 receptor

Molecular cloning of the human histamine H2 receptor

by Gantz, Ira, Munzert, Gerd, Tashiro, Takao, Schäffer, Matthias, Wang, Lidong, DelValle, John, Yamada, Tadataka
Published in Biochemical and biophysical research communications (15.08.1991)

Get full text

Journal Article

The SH2-containing adapter protein GRB10 interacts with BCR-ABL

The SH2-containing adapter protein GRB10 interacts with BCR-ABL

by REN YUAN BAI, JAHN, T, SCHREM, S, MUNZERT, G, WEIDNER, K. M, WANG, J. Y. J, DUYSTER, J
Published in Oncogene (27.08.1998)

Get full text

Journal Article

The Efficacy and Safety of BI 2536, a Novel Plk-1 Inhibitor, in Patients with Stage IIIB/IV Non-small Cell Lung Cancer Who Had Relapsed after, or Failed, Chemotherapy: Results from an Open-Label, Randomized Phase II Clinical Trial

The Efficacy and Safety of BI 2536, a Novel Plk-1 Inhibitor, in Patients with Stage IIIB/IV Non-small Cell Lung Cancer Who Had Relapsed after, or Failed, Chemotherapy: Results from an Open-Label, Randomized Phase II Clinical Trial

by Sebastian, Martin, Reck, Martin, Waller, Cornelius F., Kortsik, Cornelius, Frickhofen, Norbert, Schuler, Martin, Fritsch, Holger, Gaschler-Markefski, Birgit, Hanft, Gertraud, Munzert, Gerd, von Pawel, Joachim
Published in Journal of thoracic oncology (01.07.2010)

Get full text

Journal Article

$Treatment with AMG 420, an Anti-B-Cell Maturation Antigen (BCMA) Bispecific T-Cell Engager (BiTE®) Antibody Construct, Induces Minimal Residual Disease (MRD) Negative Complete Responses in Relapsed and/or Refractory (R/R) Multiple Myeloma (MM) Patients: Results of a First-in-Human (FIH) Phase I Dose Escalation Study$

Treatment with AMG 420, an Anti-B-Cell Maturation Antigen (BCMA) Bispecific T-Cell Engager (BiTE®) Antibody Construct, Induces Minimal Residual Disease (MRD) Negative Complete Responses in Relapsed and/or Refractory (R/R) Multiple Myeloma (MM) Patients: Results of a First-in-Human (FIH) Phase I Dose Escalation Study

by Topp, Max S., Duell, Johannes, Zugmaier, Gerhard, Attal, Michel, Moreau, Philippe, Langer, Christian, Kroenke, Jan, Facon, Thierry, Einsele, Hermann, Munzert, Gerd
Published in Blood (29.11.2018)

Get full text

Journal Article

An Open-Label, Phase II Study of the Polo-like Kinase-1 (Plk-1) Inhibitor, BI 2536, in Patients with Relapsed Small Cell Lung Cancer (SCLC)

An Open-Label, Phase II Study of the Polo-like Kinase-1 (Plk-1) Inhibitor, BI 2536, in Patients with Relapsed Small Cell Lung Cancer (SCLC)

by Awad, Mark M, Chu, Quincy S-C, Gandhi, Leena, Stephenson, Joe J, Govindan, Ramaswamy, Bradford, Daniel S, Bonomi, Philip D, Ellison, David M, Eaton, Keith D, Fritsch, Holger, Munzert, Gerd, Johnson, Bruce E, Socinski, Mark A
Published in Lung cancer (Amsterdam, Netherlands) (01.02.2017)

Get full text

Journal Article

An Open-Label, Phase I Study of the Polo-like Kinase-1 Inhibitor, BI 2536, in Patients with Advanced Solid Tumors

An Open-Label, Phase I Study of the Polo-like Kinase-1 Inhibitor, BI 2536, in Patients with Advanced Solid Tumors

by HOFHEINZ, Ralf-Dieter, AL-BATRAN, Salah-Eddin, HOCHHAUS, Andreas, JÄGER, Elke, REICHARDT, Volker L, FRITSCH, Holger, TROMMESHAUSER, Dirk, MUNZERT, Gerd
Published in Clinical cancer research (15.09.2010)

Get full text

Journal Article

Evaluation of AMG 420, an anti-BCMA bispecific T-cell engager (BiTE) immunotherapy, in R/R multiple myeloma (MM) patients: Updated results of a first-in-human (FIH) phase I dose escalation study

Evaluation of AMG 420, an anti-BCMA bispecific T-cell engager (BiTE) immunotherapy, in R/R multiple myeloma (MM) patients: Updated results of a first-in-human (FIH) phase I dose escalation study

by Topp, Max S., Duell, Johannes, Zugmaier, Gerhard, Attal, Michel, Moreau, Philippe, Langer, Christian, Kroenke, Jan, Facon, Thierry, Salnikov, Alexey, Lesley, Robin, Beutner, Karl, Kalabus, James, Rasmussen, Erik, Riemann, Kathrin, Minella, Alex C., Munzert, Gerd Michael, Einsele, Hermann
Published in Journal of clinical oncology (20.05.2019)

Get full text

Journal Article

Multicentric parallel phase II trial of the polo-like kinase 1 inhibitor BI 2536 in patients with advanced head and neck cancer, breast cancer, ovarian cancer, soft tissue sarcoma and melanoma. The first protocol of the European Organization for Research and Treatment of Cancer (EORTC) Network Of Core Institutes (NOCI)

Multicentric parallel phase II trial of the polo-like kinase 1 inhibitor BI 2536 in patients with advanced head and neck cancer, breast cancer, ovarian cancer, soft tissue sarcoma and melanoma. The first protocol of the European Organization for Research and Treatment of Cancer (EORTC) Network Of Core Institutes (NOCI)

by Schöffski, Patrick, Blay, Jean-Yves, De Greve, Jacques, Brain, Etienne, Machiels, Jean-Pascal, Soria, Jean-Charles, Sleijfer, Stefan, Wolter, Pascal, Ray-Coquard, Isabelle, Fontaine, Christel, Munzert, Gerd, Fritsch, Holger, Hanft, Gertraud, Aerts, Claire, Rapion, Jérome, Allgeier, Anouk, Bogaerts, Jan, Lacombe, Denis
Published in European journal of cancer (1990) (01.08.2010)

Get full text

Journal Article

$Phase 1 dose-escalation study of BI 836909, an anti-BCMA bi-specific T-cell engager, in relapsed and/or refractory multiple myeloma (RRMM)$

Phase 1 dose-escalation study of BI 836909, an anti-BCMA bi-specific T-cell engager, in relapsed and/or refractory multiple myeloma (RRMM)

by Topp, Max S., Attal, Michel, Langer, Christian, Moreau, Philippe, Facon, Thierry, Düll, Johannes, Hebraud, Benjamin, Gomez-Roca, Carlos, Munzert, Gerd Michael, Gracien, Edith, Zugmaier, Gerhard, Einsele, Hermann
Published in Journal of clinical oncology (20.05.2016)

Get full text

Journal Article

$A randomized, open‐label, phase I/II trial to investigate the maximum tolerated dose of the Polo‐like kinase inhibitor BI 2536 in elderly patients with refractory/relapsed acute myeloid leukaemia$

A randomized, open‐label, phase I/II trial to investigate the maximum tolerated dose of the Polo‐like kinase inhibitor BI 2536 in elderly patients with refractory/relapsed acute myeloid leukaemia

by Müller‐Tidow, Carsten, Bug, Gesine, Lübbert, Michael, Krämer, Alwin, Krauter, Jürgen, Valent, Peter, Nachbaur, David, Berdel, Wolfgang E., Ottmann, Oliver G., Fritsch, Holger, Munzert, Gerd, Garin‐Chesa, Pilar, Fleischer, Frank, Taube, Tillmann, Döhner, Hartmut
Published in British journal of haematology (01.10.2013)

Get full text

Journal Article

DIHYDROPTERIDINONES FOR THE TREATMENT OF CANCER DISEASES

DIHYDROPTERIDINONES FOR THE TREATMENT OF CANCER DISEASES

by STEEGMAIER MARTIN, MUNZERT GERD
Year of Publication 30.04.2013

Get full text

Patent

1
2
3
4
5
6
7
8
9
10
11
Next
[12]